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EditordSerrao and Goodchild1 have correctly identified an 
author’s error2 for which I apologise. The lipid-free presentation 
of an i.v. anaesthetic is a sensible ambition, and their 
strategy of formulating alphaxalone in a 7-sulphobutyl ether 
b-cyclodextrin solution 13% is rational. Their preliminary 
publications confirm that, in this vehicle, alphaxalone maintains 
its characteristic of haemodynamic stability whilst being 
somewhat less lethal to rats than alphaxalone in Cremophor 
EL 20%.3 
I am also hopeful for new i.v. anaesthetics, but enthusiasm 
has to be grounded against the universal availability of lowpriced 
generic propofol. To achieve commercial success will 
require satisfying regulators that the vehicle is safe and 
persuading anaesthetists that the haemodynamic improvements 
are important. 
Sulphobutyl ether b-cyclodextrin is already used as a 
vehicle for injectables, but in very different volumes to those 
required for total i.v. anaesthesia and intensive care sedation. 
Clinicians often administer medicines outwith their licensed 
doses and indications, so considering the extremes is appropriate. 
When alphaxalone formulated as Althesin (alphaxalone 
9 mg ml_1 and alphadolone 3 mg ml_1) was used for 
intensive care unit sedation, the average infusion rate for 
sedation was 0.079 ml_1 kg_1 h_1, and one patient weighing 
55 kg received a total of 4367 ml (79.4 ml kg_1) infused at 
0.2339 ml_1 kg h_1.4 At present, the relative potencies of 
alphaxalone in sulphobutyl ether b-cyclodextrin 13% and 
Althesin have not been reported. Nevertheless, sulphobutyl 
ether b-cyclodextrin 13%, 0.079 ml kg_1 h_1 would present a 
cyclodextrin dose of 246.5 mg kg_1 day_1. Sulphobutyl ether 
bcyclodextrin 
13%, 79.4 ml kg_1 is a dose of 10 322 mg kg_1. 
Renal and hepatic toxicities have been described in rats 
receiving sulphobutyl ether b-cyclodextrin 3000 mg kg_1 albeit 
over a shorter period.5 
Haemodynamic stability with alphaxalone is certainly superior 
to propofol6; however, virtually any patient may be 
safely anaesthetised with propofol in judicious doses. Bell and 
Goodchild7 have described the safety of i.v. anaesthesia with 
propofol in a patient with hypertrophic obstructive cardiomyopathy 
and aortic obstruction. 
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